HK StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Nonprofit Pharmaceutical Companies

756.444

+3.6790.49%

Number of Gainers:14

Number of Losers:19

Number of Flat:1

PE:- -

High:759.807

Open:752.766

Low:731.811

Close:752.766

Volume:245.95M

Turnover:5.87B

Market Cap:446.90B

Float Cap:412.47B

Loading ...

BRIEF-Alphamab Oncology's JSKN003 Receives FDA Approval

Zhaoke Secures US FDA Orphan Drug Status for Pediatric Eye Cancer Drug; Shares Lose 1%

MT Newswires Live

Alphamab Oncology Receives U.S. FDA Approval to Initiate Phase II Clinical Study for JSKN003 in Treating Platinum-Resistant Ovarian Cancer

Alphamab Oncology - Jskn003 Receives FDA Approval for Phase Ii Clinical Study

THOMSON REUTERS

Akeso Inc. Announces Launch of Phase III Clinical Trial for Ivonescimab in Treatment of IO-Resistant NSCLC

Akeso Announces Completion of First Dosing in Phase Iii Clinical Trial of Ivonescimab (Pd-1/Vegf) Combination Therapy for Immunotherapy-Resistant Nsclc

THOMSON REUTERS

Ocumension Therapeutics' (HKG:1477) Shift From Loss To Profit

Simply Wall St.

Zhaoke Ophthalmology Ltd. Receives FDA Orphan Drug Designation for Melphalan Targeting Pediatric Retinoblastoma

Zhaoke Ophthalmology - US FDA Grants Orphan Drug Designation to Zhaoke's Melphalan

THOMSON REUTERS

Harbour BioMed Announces Phase II Clinical Data Presentation of HBM4003 and Tislelizumab Combo for MSS Metastatic Colorectal Cancer at ESMO 2025

Is Peijia Medical Limited (HKG:9996) Trading At A 44% Discount?

Simply Wall St.

RemeGen Co., Ltd.'s (HKG:9995) Shares Climb 26% But Its Business Is Yet to Catch Up

Simply Wall St.

Jacobio Pharmaceuticals Group - Purchased 60,900 Shares at HK$7.16 per Share From July 24-29

THOMSON REUTERS

Jacobio Pharmaceuticals' Concert Parties Increase Holdings, Purchasing 60,900 Shares at HK$7.16 Each

Shanghai HeartCare Medical Technology Corp. Announces Positive Profit Forecast with Expected RMB40 Million Net Profit Turnaround

HEARTCARE-B (06609) Issues Profit Alert, Expects Interim Profit Attributable to Shareholders of at Least RMB 40 Million in Significant YoY Turnaround

Shanghai HeartCare Medical Technology - Sees Increase in Revenue in Hy

THOMSON REUTERS

Shanghai HeartCare Medical Technology Corp - Group Expects Hy Net Profit of at Least RMB40 Mln

THOMSON REUTERS

BUZZ-HK-listed Antengene at 2-1/2-year peak on Xpovio approval in China

BRIEF-Alphamab Oncology Says Jskn003 Granted Orphan Drug Designation By U.S. FDA

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BK1574/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1574","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","market":"HK","secType":"PLATE","nameCN":"Nonprofit Pharmaceutical Companies","latestPrice":756.4441,"timestamp":1754640483916,"preClose":752.76556,"halted":0,"volume":245946369,"delay":0,"changeRate":0.004887,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Market Closed","change":3.678528,"latestTime":"08-08 16:00:00","open":752.76556,"high":759.8065,"low":731.8107,"amount":5871661389.5,"amplitude":0.037191,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1754875800000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1754616600000,1754625600000],[1754629200000,1754640000000]],"pbRate":6.123728,"peRate":-38.625124,"turnoverRate":0.009192,"increases":14,"decrements":17,"flats":2,"marketCap":446904094912,"floatMarketCap":412466656768},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","high":759.8065,"amplitude":0.037191,"preClose":752.76556,"low":731.8107,"pbRate":"6.123728","latestPrice":756.4441,"volume":245946369,"delay":0,"open":752.76556,"prevYearClose":331.1933,"prevWeekClose":721.922,"prevMonthClose":735.033,"prevQuarterClose":555.617,"fiveDayClose":721.922,"twentyDayClose":607.346,"sixtyDayClose":449.278,"secType":"PLATE","market":"HK","turnoverRate":0.009192,"peRate":-38.625124,"marketCap":446904094912,"floatMarketCap":412466656768,"timestamp":1754640483916,"nameCN":"Nonprofit Pharmaceutical Companies"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1574\",,,,undefined,":{"bkCode":"BK1574","up":14,"down":19,"flat":1},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1574\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2555009209","title":"BRIEF-Alphamab Oncology's JSKN003 Receives FDA Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2555009209","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555009209?lang=en_us&edition=fundamental","pubTime":"2025-07-31 15:00","pubTimestamp":1753945252,"startTime":"0","endTime":"0","summary":"BRIEF-Alphamab Oncology's JSKN003 Receives FDA ApprovalJuly 31 (Reuters) - Alphamab Oncology 9966.HK:JSKN003 RECEIVES FDA APPROVAL FOR PHASE II CLINICAL STUDYFurther company coverage: 9966.HK ((Reuters.Briefs@thomsonreuters.com;))","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250731:nFWN3TR2C9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09966","BK1161","BK1574"],"gpt_icon":0},{"id":"2555907061","title":"Zhaoke Secures US FDA Orphan Drug Status for Pediatric Eye Cancer Drug; Shares Lose 1%","url":"https://stock-news.laohu8.com/highlight/detail?id=2555907061","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555907061?lang=en_us&edition=fundamental","pubTime":"2025-07-31 12:41","pubTimestamp":1753936915,"startTime":"0","endTime":"0","summary":"Zhaoke Ophthalmology  said its proprietary formulation of melphalan has received orphan drug designation from the US Food and Drug Administration for the treatment of pediatric retinoblastoma, according to a Wednesday bourse filing.Shares of the company declined by over 1% in Thursday's recent trade.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1583","BK1587","06622","BK1191","BK1574"],"gpt_icon":0},{"id":"2555771930","title":"Alphamab Oncology Receives U.S. FDA Approval to Initiate Phase II Clinical Study for JSKN003 in Treating Platinum-Resistant Ovarian Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2555771930","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555771930?lang=en_us&edition=fundamental","pubTime":"2025-07-31 12:07","pubTimestamp":1753934867,"startTime":"0","endTime":"0","summary":"Alphamab Oncology Receives U.S. FDA Approval to Initiate Phase II Clinical Study for JSKN003 in Treating Platinum-Resistant Ovarian Cancer. Alphamab Oncology, a leading biopharmaceutical company in China, has received approval from the U.S. Food and Drug Administration  to initiate a Phase II clinical study for its drug candidate, JSKN003. This study, identified as JSKN003-202, will focus on the treatment of patients with platinum-resistant recurrent epithelial ovarian cancer, primary peritoneal, or fallopian tube cancer, collectively known as platinum-resistant ovarian cancer . The study will be randomized, open-label, and multi-center. This advancement highlights Alphamab Oncology's proprietary protein engineering expertise and commitment to developing next-generation biological drug candidates. The company has not specified any collaboration with other organizations regarding this regulatory approval.Disclaimer: This news brief was created by Public Technologies  using generative ar","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250731:nNDL67kdfS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1574","09966"],"gpt_icon":0},{"id":"2555077591","title":"Alphamab Oncology - Jskn003 Receives FDA Approval for Phase Ii Clinical Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2555077591","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555077591?lang=en_us&edition=fundamental","pubTime":"2025-07-31 12:00","pubTimestamp":1753934450,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250731:nFWN3TR2C9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","BK1574","09966"],"gpt_icon":0},{"id":"2555607999","title":"Akeso Inc. Announces Launch of Phase III Clinical Trial for Ivonescimab in Treatment of IO-Resistant NSCLC","url":"https://stock-news.laohu8.com/highlight/detail?id=2555607999","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555607999?lang=en_us&edition=fundamental","pubTime":"2025-07-31 09:47","pubTimestamp":1753926439,"startTime":"0","endTime":"0","summary":"Akeso Inc. has announced the initiation of a Phase III clinical trial involving ivonescimab, a PD-1/VEGF bispecific antibody, in combination with docetaxel for the treatment of locally advanced or metastatic non-small cell lung cancer  that has progressed following PD-1/L1 inhibitors and platinum-based chemotherapy. This pivotal study, AK112-305/HARMONi-8A, recently dosed its first patient. Ivonescimab is notable for being the only bispecific immunotherapy antibody currently in Phase III registration trials for immunotherapy-resistant lung cancer. The trial aims to provide a novel treatment option for patients with IO-resistant NSCLC, leveraging the synergistic effects of targeting both PD-1 and VEGF pathways to reactivate anti-tumor immune responses. The results of this ongoing study have not yet been presented.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250731:nNDL75mxhk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","LU1720050803.USD","LU2488822045.USD","IE00BPRC5H50.USD","LU0348784397.USD","BK1574","LU1794554557.SGD","IE00B543WZ88.USD","09926","LU0417516571.SGD","IE00B5MMRT66.SGD","LU0348783233.USD"],"gpt_icon":0},{"id":"2555079964","title":"Akeso Announces Completion of First Dosing in Phase Iii Clinical Trial of Ivonescimab (Pd-1/Vegf) Combination  Therapy for Immunotherapy-Resistant Nsclc","url":"https://stock-news.laohu8.com/highlight/detail?id=2555079964","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555079964?lang=en_us&edition=fundamental","pubTime":"2025-07-31 09:47","pubTimestamp":1753926424,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250731:nTUA4Y6W9Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IE00B5MMRT66.SGD","BK1574","IE00B543WZ88.USD","IE00BPRC5H50.USD","LU1794554557.SGD","LU2488822045.USD","LU0348784397.USD","09926","BK1161","LU1720050803.USD","LU0417516571.SGD","LU0348783233.USD"],"gpt_icon":0},{"id":"2555207447","title":"Ocumension Therapeutics' (HKG:1477) Shift From Loss To Profit","url":"https://stock-news.laohu8.com/highlight/detail?id=2555207447","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555207447?lang=en_us&edition=fundamental","pubTime":"2025-07-31 07:58","pubTimestamp":1753919938,"startTime":"0","endTime":"0","summary":"We feel now is a pretty good time to analyse Ocumension Therapeutics' ( HKG:1477 ) business as it appears the company...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1477/ocumension-therapeutics-shares/news/ocumension-therapeutics-hkg1477-shift-from-loss-to-profit","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1574","01477","BK4007","BK1191","LENZ","BK4139","BK4539"],"gpt_icon":0},{"id":"2555045807","title":"Zhaoke Ophthalmology Ltd. Receives FDA Orphan Drug Designation for Melphalan Targeting Pediatric Retinoblastoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2555045807","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555045807?lang=en_us&edition=fundamental","pubTime":"2025-07-30 19:10","pubTimestamp":1753873837,"startTime":"0","endTime":"0","summary":"Zhaoke Ophthalmology Ltd. has announced that the U.S. Food and Drug Administration  has granted Orphan Drug Designation  to its proprietary formulation of melphalan for the treatment of pediatric retinoblastoma, a rare pediatric eye cancer. This designation provides a clear regulatory pathway toward the submission of an Investigational New Drug  application in the U.S. If successfully developed and approved, Zhaoke Ophthalmology Ltd. would be eligible for seven years of market exclusivity in the U.S. upon New Drug Application  approval. This exclusivity includes marketing authorization holder status and data exclusivity, offering comprehensive protection in the market.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zhaoke Ophthalmology","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250730:nNDL2KYNbP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1587","BK1574","06622","BK1583","BK1191"],"gpt_icon":0},{"id":"2555043263","title":"Zhaoke Ophthalmology - US FDA Grants Orphan Drug Designation to Zhaoke's Melphalan","url":"https://stock-news.laohu8.com/highlight/detail?id=2555043263","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555043263?lang=en_us&edition=fundamental","pubTime":"2025-07-30 19:06","pubTimestamp":1753873599,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250730:nFWN3TR11G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1191","06622","BK1583","BK1587","BK1574"],"gpt_icon":0},{"id":"2555610067","title":"Harbour BioMed Announces Phase II Clinical Data Presentation of HBM4003 and Tislelizumab Combo for MSS Metastatic Colorectal Cancer at ESMO 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2555610067","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555610067?lang=en_us&edition=fundamental","pubTime":"2025-07-30 08:02","pubTimestamp":1753833730,"startTime":"0","endTime":"0","summary":"Harbour BioMed Announces Phase II Clinical Data Presentation of HBM4003 and Tislelizumab Combo for MSS Metastatic Colorectal Cancer at ESMO 2025. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HBM Holdings Ltd. published the original content used to generate this news brief via PR Newswire  on July 30, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250730:nNDL5dHmkZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02142","BK1583","BK1574"],"gpt_icon":0},{"id":"2555448320","title":"Is Peijia Medical Limited (HKG:9996) Trading At A 44% Discount?","url":"https://stock-news.laohu8.com/highlight/detail?id=2555448320","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555448320?lang=en_us&edition=fundamental","pubTime":"2025-07-30 07:35","pubTimestamp":1753832158,"startTime":"0","endTime":"0","summary":"Key Insights Peijia Medical's estimated fair value is HK$15.63 based on 2 Stage Free Cash Flow to Equity Current share...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6021000-choice2-main-header/1585186837163","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6021000-choice2-main-header/1585186837163"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/healthcare/hkg-9996/peijia-medical-shares/news/is-peijia-medical-limited-hkg9996-trading-at-a-44-discount","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1100","BK1583","TV","BK4211","BK4100","BK1574","09996","DCF","FCF"],"gpt_icon":0},{"id":"2555609391","title":"RemeGen Co., Ltd.'s (HKG:9995) Shares Climb 26% But Its Business Is Yet to Catch Up","url":"https://stock-news.laohu8.com/highlight/detail?id=2555609391","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555609391?lang=en_us&edition=fundamental","pubTime":"2025-07-30 06:34","pubTimestamp":1753828463,"startTime":"0","endTime":"0","summary":"Despite an already strong run, RemeGen Co., Ltd. ( HKG:9995 ) shares have been powering on, with a gain of 26% in the...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9995/remegen-shares/news/remegen-co-ltds-hkg9995-shares-climb-26-but-its-business-is","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1574","BK1161","LU2328871848.SGD","BK1583","LU1969619763.USD","09995"],"gpt_icon":0},{"id":"2555064783","title":"Jacobio Pharmaceuticals Group - Purchased 60,900 Shares at HK$7.16 per Share From July 24-29","url":"https://stock-news.laohu8.com/highlight/detail?id=2555064783","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555064783?lang=en_us&edition=fundamental","pubTime":"2025-07-30 06:03","pubTimestamp":1753826636,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250729:nFWN3TQ1H9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["01167","BK1161","BK1574"],"gpt_icon":0},{"id":"2555064733","title":"Jacobio Pharmaceuticals' Concert Parties Increase Holdings, Purchasing 60,900 Shares at HK$7.16 Each","url":"https://stock-news.laohu8.com/highlight/detail?id=2555064733","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555064733?lang=en_us&edition=fundamental","pubTime":"2025-07-30 06:03","pubTimestamp":1753826624,"startTime":"0","endTime":"0","summary":"Jacobio Pharmaceuticals Group Co. Ltd. announced that members of the parties acting in concert with the company purchased a total of 60,900 shares on the open market between July 24 and July 29, 2025, at an average price of HK$7.16 per share. This transaction is part of a recent acquisition of 1,155,300 shares, bringing the Concert Parties' total holdings to 200,755,285 shares, representing approximately 25.36% of the company's total issued shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jacobio Pharmaceuticals Group Co. Ltd. published the original content used to generate this news brief on July 30, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250729:nNDL7yRCwb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1161","01167"],"gpt_icon":0},{"id":"2555396130","title":"Shanghai HeartCare Medical Technology Corp. Announces Positive Profit Forecast with Expected RMB40 Million Net Profit Turnaround","url":"https://stock-news.laohu8.com/highlight/detail?id=2555396130","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555396130?lang=en_us&edition=fundamental","pubTime":"2025-07-29 17:12","pubTimestamp":1753780366,"startTime":"0","endTime":"0","summary":"Shanghai HeartCare Medical Technology Corp. Announces Positive Profit Forecast with Expected RMB40 Million Net Profit Turnaround. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai HeartCare Medical Technology Corporation Ltd. published the original content used to generate this news brief on July 29, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250729:nNDL5kfzfZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1100","BK1587","06609","BK1574"],"gpt_icon":0},{"id":"1114792358","title":"HEARTCARE-B (06609) Issues Profit Alert, Expects Interim Profit Attributable to Shareholders of at Least RMB 40 Million in Significant YoY Turnaround","url":"https://stock-news.laohu8.com/highlight/detail?id=1114792358","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1114792358?lang=en_us&edition=fundamental","pubTime":"2025-07-29 17:08","pubTimestamp":1753780115,"startTime":"0","endTime":"0","summary":"HEARTCARE-B (06609) has announced a positive profit alert, projecting that its interim profit attributable to shareholders will reach no less than RMB 40 million. This marks a substantial year-on-year shift from losses to profitability.","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06609","BK1100","BK1574","BK1587"],"gpt_icon":0},{"id":"2555393470","title":"Shanghai HeartCare Medical Technology - Sees Increase in Revenue in Hy","url":"https://stock-news.laohu8.com/highlight/detail?id=2555393470","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555393470?lang=en_us&edition=fundamental","pubTime":"2025-07-29 17:03","pubTimestamp":1753779783,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250729:nFWN3TP25O:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1587","06609","BK1574","BK1100"],"gpt_icon":0},{"id":"2555036018","title":"Shanghai HeartCare Medical Technology Corp - Group Expects Hy Net Profit of at Least RMB40 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2555036018","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555036018?lang=en_us&edition=fundamental","pubTime":"2025-07-29 17:03","pubTimestamp":1753779783,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250729:nFWN3TP25O:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1574","06609","BK1100","BK1587"],"gpt_icon":0},{"id":"2555608693","title":"BUZZ-HK-listed Antengene at 2-1/2-year peak on Xpovio approval in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2555608693","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555608693?lang=en_us&edition=fundamental","pubTime":"2025-07-29 10:55","pubTimestamp":1753757734,"startTime":"0","endTime":"0","summary":"BUZZ-HK-listed Antengene at 2-1/2-year peak on Xpovio approval in China** Shares of Antengene Corp 6996.HK rise 5.6% to HK$5.84** Stock at highest level since Feb 2023, set for sixth consecutive session of gains** Innovative oncology medicines-focused clinical-stage biopharmaceutical group says its Xpovio approved in China for second-line treatment of multiple myeloma** Hang Seng Biotech Index .HSHKBIO rises 2.6%, while benchmark Hang Seng Index .HSI falls 1.1%** YTD, stock up 783%  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250729:nL1N3TQ02P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","BK1574","06996","BK1191"],"gpt_icon":0},{"id":"2555608801","title":"BRIEF-Alphamab Oncology Says Jskn003 Granted Orphan Drug Designation By U.S. FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2555608801","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555608801?lang=en_us&edition=fundamental","pubTime":"2025-07-29 09:41","pubTimestamp":1753753266,"startTime":"0","endTime":"0","summary":"BRIEF-Alphamab Oncology Says Jskn003 Granted Orphan Drug Designation By U.S. FDAJuly 29 (Reuters) - Alphamab Oncology 9966.HK:JSKN003 GRANTED ORPHAN DRUG DESIGNATION BY U.S. FDAFurther company coverage: 9966.HK ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250729:nFWN3TP2BJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1161","09966"],"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":4,"totalSize":102,"code":"91000000","status":"200"}]}}